Cancer Drug Design and Discovery
A Color Guide
Series: Advances in Planar Lipid Bilayers and Liposomes; 2;
- Publisher's listprice EUR 81.95
-
33 988 Ft (32 370 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 3 399 Ft off)
- Discounted price 30 590 Ft (29 133 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
33 988 Ft
Availability
Out of print
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2
- Publisher Elsevier Science
- Date of Publication 30 November 2007
- ISBN 9780123694485
- Binding Hardback
- No. of pages496 pages
- Size 260x184 mm
- Weight 1310 g
- Language English 0
Categories
Long description:
The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.
MoreTable of Contents:
Section I. Basic Principles
1. Modern cancer drug discovery: Integrating targets, technologies and treatments
2. Preclinical pharmacology and in vivo models
3. Clinical trial designs for more rapid proof-of-principle and approval
Section II. Methodology
4. Structural biology and anticancer drug design
5. Natural product chemistry and cancer drug discovery
6. Pharmacokinetics & ADME optimization in drug discovery
Section III. Drugs in the clinic and laboratory
7. Temozolomide: from cytotoxic to molecularly-targeted agent
8. Camptothecins for drug design, cancer cell death and gene targeting
9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
Section IV. New Agents
10. Targeting inactive kinases: structure as a foundation for cancer drug discovery
11. Cell cycle inhibitors in cancer: current status and future directions
12. Inhibition of DNA repair as a therapeutic target
13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
14. Heat shock protein-90-directed therapeutics and target validation
15. Inhibitors of tumour angiogenesis
16. The biology and oncology of RAF-ERK signalling P53 as a therapeutic target
Section V. The reality of cancer drugs in the clinic
17. Cancer drug resistance
18. Failure Modes in Anticancer Drug Discovery and Development
